HCC-话题@MedSci

#HCC#

114篇内容 | 2420人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259480, encodeId=7dab125948060, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：他汀类药物可帮助HCV患者降低肝硬化和HCC风险, objectType=article, longId=64398, objectId=79bb643989a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79bb643989a, replyNumber=0, likeNumber=27, createdTime=2016-03-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79bb643989a, moduleTitle=Hepatology：他汀类药物可帮助HCV患者降低肝硬化和HCC风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79bb643989a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259479, encodeId=58da12594e93e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：慢乙肝患者发生了自发性HBsAg清除后，还需要进行HCC监测吗？, objectType=article, longId=44855, objectId=c021448557a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c021448557a, replyNumber=0, likeNumber=32, createdTime=2015-01-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c021448557a, moduleTitle=J Hepatol：慢乙肝患者发生了自发性HBsAg清除后，还需要进行HCC监测吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c021448557a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259478, encodeId=b85512594e829, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力, objectType=article, longId=41810, objectId=d76d4181080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d76d4181080, replyNumber=0, likeNumber=33, createdTime=2014-10-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d76d4181080, moduleTitle=Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d76d4181080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259477, encodeId=6ea012594e77d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=2012 CHCC 血管炎新分类标准启示, objectType=article, longId=38493, objectId=03b43849354, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03b43849354, replyNumber=0, likeNumber=30, createdTime=2014-08-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03b43849354, moduleTitle=2012 CHCC 血管炎新分类标准启示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03b43849354)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259476, encodeId=92db12594e680, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：手术与射频消融治疗无门脉高压的HCC效果相似, objectType=article, longId=33354, objectId=26d633354c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d633354c9, replyNumber=0, likeNumber=40, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d633354c9, moduleTitle=EASL 2014：手术与射频消融治疗无门脉高压的HCC效果相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26d633354c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259475, encodeId=f0ae12594e546, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：钆塞酸为造影剂的MRI对HCC分期可改善患者预后, objectType=article, longId=33353, objectId=a8a033353b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8a033353b4, replyNumber=0, likeNumber=36, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8a033353b4, moduleTitle=EASL 2014：钆塞酸为造影剂的MRI对HCC分期可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8a033353b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259474, encodeId=69bf12594e437, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估, objectType=article, longId=33350, objectId=08053335022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08053335022, replyNumber=0, likeNumber=35, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08053335022, moduleTitle=EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08053335022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259473, encodeId=612012594e31d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：BCLC-B亚分类或对HCC患者预后有一定价值, objectType=article, longId=33349, objectId=cbec3334967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbec3334967, replyNumber=0, likeNumber=35, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbec3334967, moduleTitle=EASL 2014：BCLC-B亚分类或对HCC患者预后有一定价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbec3334967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=EASL 2014：肝移植供体因素应纳入移植术后HCC复发因素中, objectType=article, longId=33347, objectId=2a1b3334e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a1b3334e0a, replyNumber=0, likeNumber=37, createdTime=2014-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a1b3334e0a, moduleTitle=EASL 2014：肝移植供体因素应纳入移植术后HCC复发因素中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a1b3334e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259471, encodeId=c18212594e177, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：LSM-HCC评分可准确预测慢乙肝患者肝癌发生风险, objectType=article, longId=25617, objectId=36472561e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36472561e7d, replyNumber=0, likeNumber=34, createdTime=2013-10-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36472561e7d, moduleTitle=J Hepatol：LSM-HCC评分可准确预测慢乙肝患者肝癌发生风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36472561e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259470, encodeId=1b9f12594e0af, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, objectType=article, longId=21705, objectId=738021e0540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=738021e0540, replyNumber=0, likeNumber=44, createdTime=2013-07-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=738021e0540, moduleTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=738021e0540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259469, encodeId=a2be1259469e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Ann Surg ：NLR为HCC患者肝脏切除术后生存的独立预测因素, objectType=article, longId=20926, objectId=4e0e2092667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e0e2092667, replyNumber=0, likeNumber=32, createdTime=2013-07-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e0e2092667, moduleTitle=Ann Surg ：NLR为HCC患者肝脏切除术后生存的独立预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e0e2092667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259468, encodeId=88661259468c5, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ASO：cccDNA/ih HBV DNA比值为HBV HCC患者生存预测因素, objectType=article, longId=20244, objectId=1c5d202442d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5d202442d, replyNumber=0, likeNumber=48, createdTime=2013-06-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5d202442d, moduleTitle=ASO：cccDNA/ih HBV DNA比值为HBV HCC患者生存预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5d202442d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259467, encodeId=e64d125946efc, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=严以群：相关HCC抗病毒策略, objectType=article, longId=12972, objectId=29a6129e299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29a6129e299, replyNumber=0, likeNumber=35, createdTime=2012-12-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29a6129e299, moduleTitle=严以群：相关HCC抗病毒策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29a6129e299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259466, encodeId=b6741259466b3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=JAMA：感染HIV/HCV患者肝纤维化分期与ESLD及HCC等综合结果有关, objectType=article, longId=9007, objectId=2662900e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2662900e61, replyNumber=0, likeNumber=37, createdTime=2012-08-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2662900e61, moduleTitle=JAMA：感染HIV/HCV患者肝纤维化分期与ESLD及HCC等综合结果有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2662900e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259465, encodeId=62e11259465d9, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=索拉菲尼治疗晚期HCC控制率达到半数, objectType=article, longId=7485, objectId=61a0e4856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a0e4856c, replyNumber=0, likeNumber=32, createdTime=2012-06-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a0e4856c, moduleTitle=索拉菲尼治疗晚期HCC控制率达到半数, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a0e4856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259464, encodeId=356a125946458, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：肝细胞癌（HCC）1~2cm不确定结节是否活检？, objectType=article, longId=4069, objectId=edba4069ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edba4069ec, replyNumber=0, likeNumber=35, createdTime=2012-02-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edba4069ec, moduleTitle=Hepatology：肝细胞癌（HCC）1~2cm不确定结节是否活检？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edba4069ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：他汀类药物可帮助HCV患者降低肝硬化和HCC风险

2016-03-08

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：慢乙肝患者发生了自发性HBsAg清除后，还需要进行HCC监测吗？

2015-01-01

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Clin Cancer Res：GCP3靶向CAR T细胞HCC治疗潜力

2014-10-30

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

2012 CHCC 血管炎新分类标准启示

2014-08-02

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：手术与射频消融治疗无门脉高压的HCC效果相似

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：钆塞酸为造影剂的MRI对HCC分期可改善患者预后

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：LY2157299治疗晚期HCC的安全性剂量评估

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：BCLC-B亚分类或对HCC患者预后有一定价值

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

EASL 2014：肝移植供体因素应纳入移植术后HCC复发因素中

2014-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：LSM-HCC评分可准确预测慢乙肝患者肝癌发生风险

2013-10-23

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险

2013-07-21

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Ann Surg ：NLR为HCC患者肝脏切除术后生存的独立预测因素

2013-07-06

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

ASO：cccDNA/ih HBV DNA比值为HBV HCC患者生存预测因素

2013-06-20

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

严以群：相关HCC抗病毒策略

2012-12-14

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

JAMA：感染HIV/HCV患者肝纤维化分期与ESLD及HCC等综合结果有关

2012-08-17

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

索拉菲尼治疗晚期HCC控制率达到半数

2012-06-30

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：肝细胞癌（HCC）1~2cm不确定结节是否活检？

2012-02-19

科室
- - 订阅+
  - 更多科室
工具
服务